Cardinal Health launches legislative toolkit
- A database to learn which elected officials to contact;
- Guides on how to make communications with elected officials effective, whether by phone call, letter or by hosting a pharmacy tour;
- An explanation of key legislative language; and
- An overview of key pharmacy issues identified by state associations and by the National Community Pharmacist Association.
- The need for pharmacists to receive ‘provider status’ so they can be reimbursed for delivering certain healthcare services to patients;
- The impact that narrow insurance networks have on patient access to pharmacy care; and
- The need for community pharmacies to be fairly reimbursed for dispensing prescriptions.
Upsher-Smith launches Qudexy XR
MAPLE GROVE, Minn. — Upsher-Smith Labs announced the launch of Qudexy XR (topiramate) extended-release capsules, a once-a-day antiepileptic drug engineered to provide a smooth pharmacokinetic profile.
The drug, which was approved by the Food and Drug Administration in March, offers patients flexibility, the company said. All strengths of Qudexy XR may be swallowed whole or administered by opening the capsule and sprinkling the contents on a spoonful of soft food.
"The launch of our first branded product within our central nervous system portfolio marks a significant milestone in Upsher-Smith's history and demonstrates our focus on developing medications that can make a meaningful difference in people's lives," said Bill Pullman, MB, BS, Phd, FRACP and chief scientific officer of Upsher-Smith. "We are pleased to bring this product forward to treat specific seizure disorders and offer another treatment option to the epilepsy community."
Qudexy XR is available in 25 mg, 50 mg, 100 mg, 150 mg and 200 mg dosage strengths.
Actavis confirms patent challenge surrounding generic Zubsolv
DUBLIN — Actavis on Monday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablets, a generic version of Zubsolv from Orexo.
Orexo filed suit against Actavis on June 26 to prevent Actavis from commerializing its ANDA product before the expiration of certain U.S. patents, the company said. Actavis believes it may be the first to file for generic version of Zubsolv, based on available information.